Pipeline

Pioneering Treg-Targeted Therapies

Our broad pipeline combines three therapeutic modalities targeting Treg dysfunction:
Treg modifying biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapy.

Coya 301 (Subcutaneous Administration)
Frontotemporal Dementia
Coya 302* (Biologic Combination)
Neurodegenerative Diseases
Coya 302* (Biologic Combination)

Autoimmune Diseases

Coya 201
Neurodegenerative, Autoimmune, and Metabolic Diseases
Coya 206
Undisclosed Indications

Leveraging COYA 101 data generated in two IIT studies to advance Treg-Derived Exosomes for treatment of Neurodegenerative and Autoimmune Diseases

Coya 101 (Autologous IV Administration)
Amyotrophic Lateral Sclerosis

* Proof-of-Concept clinical data has been generated in an Investigator-Initiated Trial conducted at Houston Methodist Hospital.

Pioneering Treg-Targeted Therapies

Our broad pipeline combines three therapeutic modalities targeting Treg dysfunction: Treg modifying biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapy.

Coya 301 (Subcutaneous Administration)
Frontotemporal Dementia
Coya 302* (Biologic Combination)
Neurodegenerative Diseases
Coya 302* (Biologic Combination)

Autoimmune Diseases

Coya 201 Platform
Neurodegenerative, Autoimmune, and Metabolic Diseases

Leveraging COYA 101 data generated in two IIT studies to advance Treg-Derived Exosomes for treatment of Neurodegenerative and Autoimmune Diseases

Coya 101 (Autologous IV Administration)
Amyotrophic Lateral Sclerosis

* Proof-of-Concept clinical data has been generated in an Investigator-Initiated Trial conducted at Houston Methodist Hospital.

Pioneering Treg-Targeted Therapies

Our broad pipeline combines three therapeutic modalities targeting Treg dysfunction: Treg modifying biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapy.

COYA 301

Frontotemporal Dementia

Coya 302*

Neurodegenerative Diseases

Coya 302*

Autoimmune Diseases

Coya 201

Neurodegenerative, Autoimmune, and Metabolic Diseases

Leveraging COYA 101 data generated in two IIT studies to advance Treg-Derived Exosomes for treatment of Neurodegenerative and Autoimmune Diseases

Coya 101

Amyotrophic Lateral Sclerosis

* Proof-of-Concept clinical data has been generated in an Investigator-Initiated Trial conducted at Houston Methodist Hospital.

Treg Enhancing Biologic

COYA 301

COYA 301 is a biologic for subcutaneous administration intended to enhance Treg function in vivo for the treatment of FTD, an orphan disease of high unmet need.

We are developing biologics and biologic combinations intended to ameliorate the inflammation and lack of immune-tolerance that characterize certain neurodegenerative and autoimmune diseases, by increasing Treg suppressive and immunomodulatory functions.

COYA 301’s subcutaneous administration allows patients to be dosed in their homes, which we believe provides convenience and pharmacoeconomic advantages over existing products requiring administration in a hospital setting.

Treg-Enhancing/T Effector and Macrophage-Depleting Biologic

COYA 302

Biologic Combination | Neurodegenerative and Autoimmune Diseases

COYA 302 is a combination biologic leveraging a Treg enhancing cytokine and an immunomodulatory fusion protein. The combination enhances Treg function while suppressing activated macrophages, T effector cells, pro-inflammatory cells, and pro-inflammatory cytokines.

COYA 302 is being developed for treatment of neurodegenerative and autoimmune diseases.

Partnership/Collaboration:

Allogeneic Exosome Platform

COYA 200 Series

Treg exosomes are nanovesicles produced by Tregs and released to the bloodstream and different tissues to communicate with other cells, including pro-inflammatory T and B cells.

We are developing a Treg-Derived Exosome Platform consisting of both Allogeneic Treg-Derived exosomes and Antigen-Directed Treg-Derived Exosomes that may have unique advantages due to their nano size, non-cell characteristics, and the potential for customization and targeting. Treg-derived exosomes are manufactured following the expansion and conversion of Tregs. Treg exosomes contain different types of cargo, such as proteins, lipids and nucleic acids, and have suppressive contact-mediated receptors and proteins that are typically present on the parent Tregs, allowing them to efficiently modulate the immune and inflammatory responses.

These Treg exosomes provide an extensive arsenal of suppressive signaling components and anti-inflammatory mediators that are potentially able to suppress pro-inflammatory cascades in the body, including the brain.

Allogeneic Exosome Platform

COYA 200 Series

Treg exosomes are nanovesicles produced by Tregs and released to the bloodstream and different tissues to communicate with other cells, including pro-inflammatory T and B cells.

We are developing a Treg-Derived Exosome Platform consisting of both Allogeneic Treg-Derived exosomes and Antigen-Directed Treg-Derived Exosomes that may have unique advantages due to their nano size, non-cell characteristics, and the potential for customization and targeting. Treg-derived exosomes are manufactured following the expansion and conversion of Tregs. Treg exosomes contain different types of cargo, such as proteins, lipids and nucleic acids, and have suppressive contact-mediated receptors and proteins that are typically present on the parent Tregs, allowing them to efficiently modulate the immune and inflammatory responses.

These Treg exosomes provide an extensive arsenal of suppressive signaling components and anti-inflammatory mediators that are potentially able to suppress pro-inflammatory cascades in the body, including the brain.

Treg Cell Therapy

COYA 101

Our autologous cell therapy technology addresses Treg dysfunction driven by chronic neuroinflammation. We have been granted orphan drug designation (“ODD”) in the United States for COYA 101 for the treatment of amyotrophic lateral sclerosis (ALS).

COYA 101 has completed two studies to date- a Phase 1 and Phase 2a, both Investigator Initiated Trials (IITs). The data from these trials provide us the information needed to design a well-powered and well-controlled confirmatory clinical study to evaluate the safety and efficacy of COYA 101 for the treatment of (ALS). Leveraging the data and expanded knowledge of Treg biology, we are focused on advancing our Treg-Modifying Biologics and Exosome Platforms.

Our goal is to advance COYA 101 into a Phase 2b clinical trial with the receipt of non-dilutive funding in the form of a grant from a government organization, or by partnering with an established pharmaceutical company.

Treg-Enhancing/T Effector and Macrophage-Depleting Biologic

COYA 302

Biologic Combination | Neurodegenerative and Autoimmune Diseases

COYA 302 is a combination biologic leveraging a Treg enhancing cytokine and an immunomodulatory fusion protein. The combination enhances Treg function while suppressing activated macrophages, T effector cells, pro-inflammatory cells, and pro-inflammatory cytokines.

COYA 302 is being developed for treatment of neurodegenerative and autoimmune diseases.

Partnership/Collaboration:

Allogeneic Exosome Platform

COYA 200 Series

Neurogenerative, Autoimmune, and Metabolic Diseases

Treg exosomes are nanovesicles produced by Tregs and released to the bloodstream and different tissues to communicate with other cells, including pro-inflammatory T and B cells.

We are developing a Treg-Derived Exosome Platform consisting of both Allogeneic Treg-Derived exosomes and Antigen-Directed Treg-Derived Exosomes that may have unique advantages due to their nano size, non-cell characteristics, and the potential for customization and targeting. Treg-derived exosomes are manufactured following the expansion and conversion of Tregs. Treg exosomes contain different types of cargo, such as proteins, lipids and nucleic acids, and have suppressive contact-mediated receptors and proteins that are typically present on the parent Tregs, allowing them to efficiently modulate the immune and inflammatory responses.

These Treg exosomes provide an extensive arsenal of suppressive signaling components and anti-inflammatory mediators that are potentially able to suppress pro-inflammatory cascades in the body, including the brain.

Partnerships/Collaborations:

Allogeneic Exosome Platform

COYA 200 Series

Undisclosed Indications

Treg exosomes are nanovesicles produced by Tregs and released to the bloodstream and different tissues to communicate with other cells, including pro-inflammatory T and B cells.

We are developing a Treg-Derived Exosome Platform consisting of both Allogeneic Treg-Derived exosomes and Antigen-Directed Treg-Derived Exosomes that may have unique advantages due to their nano size, non-cell characteristics, and the potential for customization and targeting. Treg-derived exosomes are manufactured following the expansion and conversion of Tregs. Treg exosomes contain different types of cargo, such as proteins, lipids and nucleic acids, and have suppressive contact-mediated receptors and proteins that are typically present on the parent Tregs, allowing them to efficiently modulate the immune and inflammatory responses.

These Treg exosomes provide an extensive arsenal of suppressive signaling components and anti-inflammatory mediators that are potentially able to suppress pro-inflammatory cascades in the body, including the brain.

Partnerships/Collaborations:

Treg Cell Therapy

COYA 101

Autologous IV Administration | Amyotrophic Lateral Sclerosis

Our autologous cell therapy technology addresses Treg dysfunction driven by chronic neuroinflammation. We have been granted orphan drug designation (“ODD”) in the United States for COYA 101 for the treatment of amyotrophic lateral sclerosis (ALS).

COYA 101 has completed two studies to date- a Phase 1 and Phase 2a, both Investigator Initiated Trials (IITs). The data from these trials provide us the information needed to design a well-powered and well-controlled confirmatory clinical study to evaluate the safety and efficacy of COYA 101 for the treatment of (ALS). Leveraging the data and expanded knowledge of Treg biology, we are focused on advancing our Treg-Modifying Biologics and Exosome Platforms.

Our goal is to advance COYA 101 into a Phase 2b clinical trial with the receipt of non-dilutive funding in the form of a grant from a government organization, or by partnering with an established pharmaceutical company.

Partnerships/Collaborations: